Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps
Public ClinicalTrials.gov record NCT05274750. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-1 (depemokimAb iN CHrOnic Rhinosinusitis)
Study identification
- NCT ID
- NCT05274750
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 276 participants
Conditions and interventions
Conditions
Interventions
- Depemokimab (GSK3511294) Biological
- Placebo Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 21, 2022
- Primary completion
- Jul 29, 2024
- Completion
- Aug 26, 2024
- Last update posted
- Dec 2, 2025
2022 – 2024
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Tucson | Arizona | 85704 | — |
| GSK Investigational Site | Buena Park | California | 90621 | — |
| GSK Investigational Site | Los Angeles | California | 90006 | — |
| GSK Investigational Site | San Diego | California | 91942 | — |
| GSK Investigational Site | Stanford | California | 94304 | — |
| GSK Investigational Site | Temecula | California | 92592 | — |
| GSK Investigational Site | Aurora | Colorado | 80045 | — |
| GSK Investigational Site | Gainesville | Florida | 32605 | — |
| GSK Investigational Site | Tamarac | Florida | 33321 | — |
| GSK Investigational Site | Tampa | Florida | 33613 | — |
| GSK Investigational Site | Meridian | Idaho | 83642 | — |
| GSK Investigational Site | Meridian | Idaho | 83706 | — |
| GSK Investigational Site | Chicago | Illinois | 60612 | — |
| GSK Investigational Site | Lexington | Kentucky | 40509 | — |
| GSK Investigational Site | Louisville | Kentucky | 40205 | — |
| GSK Investigational Site | Boston | Massachusetts | 02135 | — |
| GSK Investigational Site | New Brunswick | New Jersey | 08901 | — |
| GSK Investigational Site | Great Neck | New York | 11021 | — |
| GSK Investigational Site | Rochester | New York | 14642 | — |
| GSK Investigational Site | Chapel Hill | North Carolina | 27599 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45267 | — |
| GSK Investigational Site | Tulsa | Oklahoma | 74137 | — |
| GSK Investigational Site | Bethlehem | Pennsylvania | 18017 | — |
| GSK Investigational Site | Providence | Rhode Island | 02914 | — |
| GSK Investigational Site | Dallas | Texas | 75390-9035 | — |
| GSK Investigational Site | Richmond | Virginia | 23235 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05274750, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 2, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05274750 live on ClinicalTrials.gov.